Literature DB >> 28754829

Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".

Andrew D Barreto1, James C Grotta2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28754829      PMCID： PMC5608620          DOI： 10.1161/STROKEAHA.117.018294

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  4 in total

1.  Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

Authors:  Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2017-05-15       Impact factor: 7.914

2.  Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.

Authors:  D C Morris; L Zhang; Z G Zhang; M Lu; K L Berens; P M Brown; M Chopp
Journal:  Stroke       Date:  2001-11       Impact factor: 7.914

3.  A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.

Authors:  I K Jang; D F Brown; R P Giugliano; H V Anderson; D Losordo; J C Nicolau; O P Dutra; O Bazzino; V M Viamonte; R Norbady; A S Liprandi; T J Massey; R Dinsmore; R P Schwarz
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

4.  Argatroban tPA stroke study: study design and results in the first treated cohort.

Authors:  Rebecca M Sugg; Jennifer K Pary; Ken Uchino; Sarah Baraniuk; Hashem M Shaltoni; Nicole R Gonzales; Robert Mikulik; Zsolt Garami; Sandi G Shaw; Dawn E Matherne; Lemuel A Moyé; Andrei V Alexandrov; James C Grotta
Journal:  Arch Neurol       Date:  2006-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.